港股異動丨藥明康德(2359.HK)一度衝高至5% 投資的北海康成或最早秋季上市
格隆匯5月26日丨藥明康德(02359.HK)盤初一度衝高至5%,現漲幅收窄至1.39%,報82.65港元,暫成交2112萬港元,最新總市值1364.7億港元。據悉,由藥明康德投資的中國製藥商北海康成,正與摩根士丹利合作,啟動在香港IPO的早期籌備工作,計劃最早在秋季上市,集資額或最多2.5億美元(約19.5億港元)。北海康成重點開發惡性腫瘤生物靶向創新藥和以罕見病為代表的精準治療等前沿技術領域。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.